U.S. government agrees to purchase 600 mln doses of Pfizer/BioNTech coronavirus vaccine candidate

U.S. government to pay $1.95 bln for vaccine doses, has option to buy up to 500 mln more

Americans will receive vaccine free of charge

Pfizer/BioNTech expect to seek FDA review of coronavirus vaccine candidate as early as October

Pfizer and BioNTech on track to begin Phase 2b/3 clinical trial later this month
Pfizer/BioNTech to make up to 100 mln doses by end 2020, potentially more than 1.3 bln by end 2021

Pfizer shares jump 1.7% premarket

BioNTech shares jump 4.7% premarket

